MINNEAPOLIS, MN, USA I August 20, 2013 I DiaMedica (TSX VENTURE:DMA), a clinical stage biopharmaceutical company, today announced that the final Type 2 diabetic patient has been enrolled in the single ascending dose (SAD) portion of the DM199 Phase I/II clinical study. The randomized, placebo-controlled, double-blinded study is evaluating three dose levels in each Type 2 diabetic patient.
“Completion of the enrollment of Type 2 Diabetic patients into the SAD portion of the Phase I/II clinical study is an important milestone in our DM199 development pathway,” said Rick Pauls, Chairman and CEO at DiaMedica. “We are looking forward to the top line results from this study which will be available in Q3 2013.”
The primary objective of the SAD portion of the ongoing Phase I/II clinical study is to evaluate acute safety, tolerability and pharmacokinetic properties for the first time in Type 2 diabetic patients, as well as the effect of DM199 on improving glucose control.
About DiaMedica
DiaMedica Inc. is a publicly traded (TSX VENTURE:DMA) clinical stage biopharmaceutical company focused on the discovery and development of novel therapies to treat diabetes and the complications associated with diabetes. DiaMedica’s lead clinical stage compound, DM199, is a recombinant human protein that represents a novel approach to treating Type 1 and Type 2 diabetes. DiaMedica is also developing a novel monoclonal antibody, DM-204 for the treatment of Type 2 diabetes, which is in preclinical development.
SOURCE: DiaMedica
Post Views: 193
MINNEAPOLIS, MN, USA I August 20, 2013 I DiaMedica (TSX VENTURE:DMA), a clinical stage biopharmaceutical company, today announced that the final Type 2 diabetic patient has been enrolled in the single ascending dose (SAD) portion of the DM199 Phase I/II clinical study. The randomized, placebo-controlled, double-blinded study is evaluating three dose levels in each Type 2 diabetic patient.
“Completion of the enrollment of Type 2 Diabetic patients into the SAD portion of the Phase I/II clinical study is an important milestone in our DM199 development pathway,” said Rick Pauls, Chairman and CEO at DiaMedica. “We are looking forward to the top line results from this study which will be available in Q3 2013.”
The primary objective of the SAD portion of the ongoing Phase I/II clinical study is to evaluate acute safety, tolerability and pharmacokinetic properties for the first time in Type 2 diabetic patients, as well as the effect of DM199 on improving glucose control.
About DiaMedica
DiaMedica Inc. is a publicly traded (TSX VENTURE:DMA) clinical stage biopharmaceutical company focused on the discovery and development of novel therapies to treat diabetes and the complications associated with diabetes. DiaMedica’s lead clinical stage compound, DM199, is a recombinant human protein that represents a novel approach to treating Type 1 and Type 2 diabetes. DiaMedica is also developing a novel monoclonal antibody, DM-204 for the treatment of Type 2 diabetes, which is in preclinical development.
SOURCE: DiaMedica
Post Views: 193